Insights
Search Results
Client Highlights
6.11.26
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
Client Highlights
7.10.25
Wilson Sonsini Advises Iambic Therapeutics on Technology and Research Collaboration with Revolution Medicines
On July 9, 2025, Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
Client Highlights
12.06.24
Wilson Sonsini Advises Saniona on Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases
On November 26, 2024, Saniona, a clinical-stage biopharmaceutical company, announced a partnership with Acadia Pharmaceuticals (Acadia) for the development and commercialization of SAN711 in neurological diseases. Saniona will receive up to $610 million, including a $28 million upfront payment and up to $582 million in development, regulatory, and commercial milestone payments, along with tiered royalties from mid-single digits to low double digits on global net sales of SAN711. In addition, Acadia will provide financial support for Saniona’s ongoing Phase 1 clinical study and preparation for the Phase 2 clinical study.
Client Highlights
3.20.24
Wilson Sonsini Advises Tempo Therapeutics on $12 Million Series A
On March 19, 2024, Tempo Therapeutics, a leading innovator in tissue engineering and regenerative medicine, announced the completion of a $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation (JJDC). Wilson Sonsini Goodrich & Rosati has represented Tempo Therapeutics since its inception as a spinout from UCLA and currently represents the company on all legal matters.
Client Highlights
2.20.24
Wilson Sonsini Advises Kinnate Biopharma on Acquisition By XOMA
On February 16, 2024, Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate. Pursuant and subject to the terms of the merger agreement, a wholly owned subsidiary of XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. The merger transaction is expected to close in the first half of 2024. Wilson Sonsini Goodrich & Rosati is advising Kinnate on the transaction.
Client Highlights
7.17.23
Wilson Sonsini Advises DTx Pharma on Acquisition by Novartis
On July 17, 2023, DTx Pharma, a preclinical-stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON™) platform, announced that it has been acquired by Novartis. Wilson Sonsini Goodrich & Rosati advised DTx Pharma on the transaction.
Client Highlights
4.25.23
Firm Advises Amphastar on Acquisition of BAQSIMI
On April 24, 2023, Eli Lilly and Company and global pharmaceutical company Amphastar announced that Lilly agreed to divest low blood sugar drug BAQSIMI to Amphastar. BAQSIMI is the first and only nasally administered glucagon for treatment of severe hypoglycemia in people with diabetes. Wilson Sonsini Goodrich & Rosati advised Amphastar on the transaction.
Client Highlights
12.09.22
Firm Advises Arcellx on $4 Billion Collaboration with Kite
On December 9, 2022, clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop and commercialize Arcellx’s lead late-stage myeloma candidate. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
2.04.22
Wilson Sonsini Represents Arcellx in Initial Public Offering
On February 4, 2022, Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. Wilson Sonsini Goodrich & Rosati is advising Acrellx on the transaction.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Arcellx, are expected to be approximately $123.8 million. In addition, Arcellx has granted the underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Arcellx. Arcellx’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 4, 2022, under the ticker symbol “ACLX.” The offering is expected to close on February 8, 2022, subject to the satisfaction of customary closing conditions. BofA Securities, SVB Leerink, Barclays, and William Blair are acting as joint book-running managers for the offering.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Arcellx, are expected to be approximately $123.8 million. In addition, Arcellx has granted the underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Arcellx. Arcellx’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 4, 2022, under the ticker symbol “ACLX.” The offering is expected to close on February 8, 2022, subject to the satisfaction of customary closing conditions. BofA Securities, SVB Leerink, Barclays, and William Blair are acting as joint book-running managers for the offering.
Client Highlights
8.24.21
Wilson Sonsini Advises Tenaya Therapeutics on $207 Million IPO
On August 3, 2021, Tenaya Therapeutics, a biotechnology company with a mission to discover, develop, and deliver curative therapies that address the underlying causes of heart disease, announced the closing of its underwritten, upsized initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,800,000 additional shares of its common stock, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering were $207.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Tenaya. All shares in the offering were offered by Tenaya. The shares began trading on the Nasdaq Global Select Market on July 30, 2021, under the ticker symbol “TNYA.”
Client Highlights
7.28.21
Wilson Sonsini Advises Aristea Therapeutics on Strategic Collaboration and $63 Million Series B Financing
On July 27, 2021, Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. Wilson Sonsini advised Aristea Therapeutics on the transaction.